Literature DB >> 388054

[Current status in the treatment of breast cancer. I. Endocrine management--change of concepts and outlook for the future (author's transl)].

U Jehn, H Sauer, W Wilmanns.   

Abstract

A renewal of interest in endocrine therapy of breast cancer is resulting from the demonstration of steroid hormone receptors in tumor cells sensitive to antiestrogens and the possibility for predicting endocrine responsiveness. Therefore new therapeutical concepts have been developed and some of the established endocrine regimens have been reduced to historical interest. It is more than doubtful that the present schematization in selecting the proper kind of endocrine treatment has any future as methodical difficulties in demonstrating hormone receptors will be overcome and the understanding of their biological function will increase.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 388054     DOI: 10.1007/bf01478547

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  33 in total

1.  Antiestrogens in the treatment of breast cancer.

Authors:  S S Legha; S K Carter
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

2.  Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast.

Authors:  S K Carter
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

3.  In vitro analysis of the hormonal basis for the sexual dimorphism in the embryonic development of the mouse mammary gland.

Authors:  K Kratochwil
Journal:  J Embryol Exp Morphol       Date:  1971-02

4.  [Rebound regression after additional hormonal treatment with ethinyl oestradiol of metastasising carcinoma of the breast in females: frequency and clinical significance (author's transl)].

Authors:  D Quednau; M Garbrecht; G Stolzenbach; H Nowakowski
Journal:  Dtsch Med Wochenschr       Date:  1978-12-22       Impact factor: 0.628

5.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

6.  Evaluation of tamoxifen dose in advanced breast cancer: a progress report.

Authors:  D C Tormey; R M Simon; M E Lippman; J M Bull; C E Myers
Journal:  Cancer Treat Rep       Date:  1976-10

Review 7.  Current status of estrogen and progesterone receptors in breast cancer.

Authors:  W L McGuire; K B Horwitz; O H Pearson; A Segaloff
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

8.  Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group.

Authors:  A C Carter; N Sedransk; R M Kelley; F J Ansfield; R G Ravdin; R W Talley; N R Potter
Journal:  JAMA       Date:  1977-05-09       Impact factor: 56.272

9.  A demonstration of androgen and estrogen receptors in a human breast cancer using a new protamine sulfate assay.

Authors:  M Lippman; K Huff
Journal:  Cancer       Date:  1976-08       Impact factor: 6.860

10.  A hydroxylapatite micromethod for measuring estrogen receptor in human breast cancer.

Authors:  R E Garola; W L McGuire
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

View more
  1 in total

1.  [Current status in the treatment of breast cancer. II. Adjuvant chemotherapy, palliative polychemotherapy, chemoimmunotherapy--rating and results (author's transl)].

Authors:  H Sauer; U Jehn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-09-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.